Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Stemcentrx Scooped Up

    I think that this deal is going to end up looking either very smart or very stupid. AbbVie is paying almost ten billion dollars to acquire Stemcentrx, the startup I first wrote about here. That’s a lot of money to put down on the idea of cancer stem cells, so the first assumption is that… Read More
  • Business and Markets

    A Look From the Short Side

    I always enjoy hearing what Jim Chanos has to say – he’s a longtime short-seller, and I think that such people provide a valuable counterpoint to the (often) clueless stock boosting that goes on. To give you an idea, he was telling people over two years ago to go short on Valeant, because he thought… Read More
  • Aging and Lifespan

    Subtle Changes Can Be Yours, for Fifty Dollars a Month

    Several people have sent me a link to Elysium Health, and I can’t say that it’s improved my morning. This is a supplement company founded by (among others) Leonard Guarente of MIT, who is of course well-known for his work in the study of longevity and aging. The company advertises a large and impressive board of… Read More
  • Business and Markets

    The Impact of Various Countries on Biopharma – Or Not

    Here’s a report looking at biopharma by country, and ranking countries based on how good an environment they provide for the industry. The three big criteria are how much their governments spend on R&D, specifically life sciences and medical R&D, how closely they regulate pharmaceutical prices, and how strong their intellectual proper… Read More
  • Business and Markets

    Cutting Back in Basel

    Hard to know what to make of this, but there are news reports in Switzerland of Roche cutting drug discovery jobs in Basel. This article says that 95 positions are going to be eliminated, but 40 more created in other parts of research, and cites rumors that immunology and infectious disease are “threatened with downsizing” Read More
  • Alzheimer's Disease

    Muscarinic Agonists Come Back Around

    Allergan, now that they’re not going to be Pfizer, has wasted no time signing a big deal with Heptares for Alzheimer’s. Heptares, as the receptor-centric people in the readership will know well, has been working on GPCR structure for some years now, and applying this knowledge to their own drug discovery efforts. They have what… Read More
  • Business and Markets

    The Treasury Wins Over Pfizer. Of Course.

    So the Pfizer-Allergan deal has collapsed. The two companys are walking away from it, since under the new rules announced by the Treasury Department, there would be no tax advantages. And this one was all about the taxes – there was no particular drug development or business rationale other than saving a big bucket on… Read More
  • Business and Markets

    Don’t Try to Leave

    The proposed Pfizer-Allergan deal has entered a new stage, and how. You’ll recall that Pfizer has been shopping for years for a way to change its US tax situation, and a merger with Dublin-domiciled Allergan looked like the one that would finally work out. Until last night, that is. That’s when the US Treasury unveiled… Read More
  • Business and Markets

    An Old Problem at Verily

    Stat has a very interesting report on what’s going on at one of Google’s biomedical companies, Verily Life Sciences. They get right down to it in the opening: Google’s brash attempt to revolutionize medicine as it did the Internet is facing turbulence, and many leaders who launched its life sciences startup have quit, STAT has found. Read More
  • Business and Markets

    You Ask For It; You Get It

    So Valeant is getting rid of their CEO, the not-so-beloved Michael Pearson, and has started to come clean about accounting problems at the company. This statement is of particular interest: The improper conduct of the company’s former Chief Financial Officer and the former Corporate Controller, which resulted in the provision of incorrect inf… Read More